Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Halothane hepatitis.

J Neuberger1, R Williams

  • 1Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.

Digestive Diseases (Basel, Switzerland)
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Halothane anesthesia can cause mild or severe hepatitis. Severe cases, possibly immune-mediated, are diagnosed by detecting antibodies against altered liver cells, and can be prevented by screening high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect on consent rates for deceased organ donation in Wales after the introduction of an opt-out system.

Anaesthesia·2020
Same author

Editorial: covert hepatic encephalopathy-silent but serious.

Alimentary pharmacology & therapeutics·2018
Same author

Confirmation of specificity of reactivity in a solid phase ELISA for the detection of hepatitis E viral antigen improves utility of the assay.

Journal of virological methods·2017
Same author

Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.

Alimentary pharmacology & therapeutics·2016
Same author

2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Area of Science:

  • Anesthesiology
  • Hepatology
  • Immunology

Background:

  • Halothane anesthesia can lead to mild or severe hepatitis.
  • The exact nature of halothane hepatitis, whether distinct entities or a spectrum, remains unclear.
  • Severe halothane hepatitis shares characteristics with immune-mediated reactions and has a high mortality rate.

Purpose of the Study:

  • To investigate the nature and diagnosis of halothane-induced hepatitis.
  • To identify risk factors and preventive strategies for halothane hepatitis.
  • To explore the potential mechanisms of liver damage in halothane hepatitis.

Main Methods:

  • Review of clinical presentations of halothane hepatitis.
  • Analysis of patient history for risk factors.

Related Experiment Videos

  • Detection of antibodies reacting with halothane-altered liver cell determinants for diagnosis.

    • Main Results:

    • Severe halothane hepatitis is more frequent after multiple exposures.
    • The incidence of severe halothane hepatitis is estimated at 1 in 3,700 multiple exposures.
    • Antibodies against halothane-altered liver cells suggest a diagnostic marker.

    Conclusions:

    • Halothane hepatitis can be diagnosed by detecting specific antibodies.
    • Preventive measures include reviewing anesthetic history and avoiding halothane in high-risk patients.
    • Treatment is supportive, with liver transplantation considered for severe cases.